Valuation: Positron Corporation

Market Cap 59.45M 51.36M 48.29M 43.93M 82.61M 5.69B 83.92M 567M 222M 2.85B 223M 218M 9.49B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 58.31M 50.38M 47.37M 43.09M 81.04M 5.58B 82.31M 556M 217M 2.79B 219M 214M 9.31B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 26/02/2018
Sales & Marketing - 23/06/2022
Corporate Officer/Principal 40 24/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%+74.47% - - 56.49M
+1.27%-3.13%-14.68%-17.72% 13.11B
+0.45%+10.77%+47.27%+18.08% 4.64B
-1.27%-0.78%-41.05%-52.57% 1.3B
-5.57%+14.91%-36.04% - 1.2B
-0.79%-1.82%-35.72%-38.35% 1.19B
-0.53%-3.01%+24.40%+80.03% 1.13B
-3.86%-7.20%+37.25%+134.70% 595M
-4.58%-7.93%+59.74% - 323M
+2.39%-1.93%-61.81%+281.50% 253M
Average -1.00%-2.59%-2.29%+57.95% 2.64B
Weighted average by Cap. +0.25%-0.34%-2.47%-0.94%

Financials

2024 2025
Net sales 588K 508K 477K 434K 816K 56.21M 829K 5.6M 2.19M 28.15M 2.21M 2.16M 93.75M 461K 399K 375K 341K 641K 44.15M 651K 4.4M 1.72M 22.11M 1.73M 1.69M 73.64M
Net income -2.38M -2.06M -1.93M -1.76M -3.31M -228M -3.36M -22.67M -8.87M -114M -8.93M -8.74M -380M -10.6M -9.16M -8.61M -7.84M -14.73M -1.01B -14.97M -101M -39.55M -508M -39.81M -38.94M -1.69B
Net Debt 1.42M 1.23M 1.16M 1.05M 1.98M 136M 2.01M 13.57M 5.31M 68.26M 5.35M 5.23M 227M -1.14M -982K -923K -840K -1.58M -109M -1.6M -10.83M -4.24M -54.44M -4.27M -4.17M -181M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-